JP2025512025A5 - - Google Patents

Info

Publication number
JP2025512025A5
JP2025512025A5 JP2024560259A JP2024560259A JP2025512025A5 JP 2025512025 A5 JP2025512025 A5 JP 2025512025A5 JP 2024560259 A JP2024560259 A JP 2024560259A JP 2024560259 A JP2024560259 A JP 2024560259A JP 2025512025 A5 JP2025512025 A5 JP 2025512025A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
seq
nos
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/088417 external-priority patent/WO2023198194A1/en
Publication of JP2025512025A publication Critical patent/JP2025512025A/ja
Publication of JP2025512025A5 publication Critical patent/JP2025512025A5/ja
Pending legal-status Critical Current

Links

JP2024560259A 2022-04-15 2023-04-14 抗cd40抗体及びその使用 Pending JP2025512025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/087003 2022-04-15
CN2022087003 2022-04-15
PCT/CN2023/088417 WO2023198194A1 (en) 2022-04-15 2023-04-14 Anti-cd40 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025512025A JP2025512025A (ja) 2025-04-16
JP2025512025A5 true JP2025512025A5 (cg-RX-API-DMAC7.html) 2026-04-21

Family

ID=88329041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560259A Pending JP2025512025A (ja) 2022-04-15 2023-04-14 抗cd40抗体及びその使用

Country Status (7)

Country Link
EP (1) EP4508088A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025512025A (cg-RX-API-DMAC7.html)
KR (1) KR20250005109A (cg-RX-API-DMAC7.html)
CN (1) CN119110807A (cg-RX-API-DMAC7.html)
AU (1) AU2023254322A1 (cg-RX-API-DMAC7.html)
CA (1) CA3256072A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023198194A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AU2016201742B2 (en) * 2010-11-15 2017-11-02 Novartis Ag Silent Fc variants of anti-CD40 antibodies
HUE065915T2 (hu) * 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
NO2699601T3 (cg-RX-API-DMAC7.html) * 2011-04-21 2018-06-16
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
WO2020014974A1 (en) * 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
KR102266788B1 (ko) Pd-1에 특이적으로 결합하는 항체 및 그의 기능성 단편
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2023549537A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
CN111757744A (zh) 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法
JP2021518108A5 (cg-RX-API-DMAC7.html)
JP2012526558A5 (cg-RX-API-DMAC7.html)
CN118317975A (zh) 靶向baff-r的抗体及其用途
JP2021520201A5 (cg-RX-API-DMAC7.html)
CN114585416A (zh) 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体
CN112074540B (zh) 细胞接合的结合分子
CN118076387A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
CN114790241B (zh) 抗tigit抗体及其应用
JP2008542321A5 (cg-RX-API-DMAC7.html)
RU2007143996A (ru) Антитела против il2
JP2025530888A5 (cg-RX-API-DMAC7.html)
JP2024533234A5 (cg-RX-API-DMAC7.html)
JP2025535503A (ja) 抗ccr8抗体及びその使用
JP2024547122A5 (cg-RX-API-DMAC7.html)
AU2020257053B2 (en) Cell engaging binding molecules
JP2024540062A5 (cg-RX-API-DMAC7.html)
RU2024129175A (ru) Анти-cd40 антитела и их применения
RU2021109816A (ru) Антитела против tnfrsf9 и их применение
RU2021104177A (ru) Антитела против cd40 и их применения